Literature DB >> 22847452

External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma.

Paolo Gontero1, Maxine Sun, Alessandro Antonelli, Roberto Bertini, Marco Carini, Giorgio Carmignani, Nicola Longo, Giuseppe Martorana, Andrea Minervini, Vincenzo Mirone, Giuseppe Morgia, Giacomo Novara, Marco Oderda, Claudio Simeone, Alchiede Simonato, Salvatore Siracusano, Alessandro Tizzani, Alessandro Volpe, Pierre Karakiewicz, Vincenzo Ficarra.   

Abstract

PURPOSE: To perform a formal external validation of the preoperative Karakiewicz nomogram (KN) for the prediction of cancer-specific survival (CSS) using a large series of surgically treated patients diagnosed with organ-confined or metastatic renal cell carcinoma (RCC).
METHODS: Patient population originated from a series of retrospectively gathered cases that underwent radical or partial nephrectomy between years 1995 and 2007 for suspicion of kidney cancer. The original Cox coefficients were used to generate the predicted risk of CSS at 1, 2, 5, and 10 years following surgery and compared to the observed risk of CSS in the current population. External validation was quantified using measures of predictive accuracy, defined as model discrimination and calibration.
RESULTS: A total of 3,374 patients were identified. Relative to the original development cohort, the current sample population had a larger proportion of patients with localized (40.0 vs. 26.3 %, P < 0.001) and non-metastatic (92.2 vs. 88.1 %, P = 0.03) disease at presentation. Model discrimination for the prediction of CSS was 87.8 % (95 % CI, 84.4-91.4) at 1 year, 87.0 % (95 % CI, 84.4-89.5) at 2 years, 84.7 % (95 % CI, 82.3-87.1) at 5 years, and 85.9 % (95 % CI, 83.2-88.6) at 10 years. The relationship between predicted and observed CSS risk was adequate in the calibration plot.
CONCLUSION: The use of the KN for the prediction of CSS in patients diagnosed with renal cell carcinoma was validated in the current study. In consequence, this tool may be recommended for routine clinical counseling in patients with various stages of RCC in the preoperative setting.

Entities:  

Mesh:

Year:  2012        PMID: 22847452     DOI: 10.1007/s00345-012-0896-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  15 in total

1.  TNM staging for renal cell carcinoma: time for a new method.

Authors:  Scott Eggener
Journal:  Eur Urol       Date:  2010-08-17       Impact factor: 20.096

2.  Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.

Authors:  Luca Cindolo; Jean-Jacques Patard; Paolo Chiodini; Luigi Schips; Vincenzo Ficarra; Jacques Tostain; Alexandre de La Taille; Vincenzo Altieri; Bernard Lobel; Richard E Zigeuner; Walter Artibani; François Guillé; Claude C Abbou; Luigi Salzano; Ciro Gallo
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

3.  The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma.

Authors:  Min-Han Tan; Huihua Li; Caroline Victoria Choong; Kee Seng Chia; Chee Keong Toh; Tiffany Tang; Puay Hoon Tan; Chin Fong Wong; Weber Lau; Christopher Cheng
Journal:  Cancer       Date:  2011-05-12       Impact factor: 6.860

4.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

5.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

6.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

7.  Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria.

Authors:  Pierre I Karakiewicz; Maxine Sun; Joaquin Bellmunt; Vesna Sneller; Bernard Escudier
Journal:  Eur Urol       Date:  2010-12-21       Impact factor: 20.096

8.  Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model.

Authors:  O Yaycioglu; W W Roberts; T Chan; J I Epstein; F F Marshall; L R Kavoussi
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

9.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Barbara A Murphy; Paul Russo; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

10.  A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma.

Authors:  Pierre I Karakiewicz; Nazareno Suardi; Umberto Capitanio; Claudio Jeldres; Vincenzo Ficarra; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Peter F A Mulders; Karim Bensalah; Walter Artibani; Laurent Salomon; Richard Zigeuner; Antoine Valéri; Jean-Luc Descotes; Jean-Jacques Rambeaud; Arnaud Méjean; Francesco Montorsi; Roberto Bertini; Jean-Jacques Patard
Journal:  Eur Urol       Date:  2008-07-25       Impact factor: 20.096

View more
  2 in total

1.  Accuracy capabilities comparisons between Karakiewicz, Kattan and Cindolo nomograms in predicting outcomes for renal cancer carcinoma: A systematic review and meta-analysis.

Authors:  Giorgio Ivan Russo; Alessandro Di Rosa; Vincenzo Favilla; Eugenia Fragalà; Tommaso Castelli; Salvatore Privitera; Sebastiano Cimino; Giuseppe Morgia
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

2.  Prognostic factors of overall survival in renal cancer patients - single oncological center study.

Authors:  Tomasz Drewniak; Marek Sandheim; Jacek Jakubowski; Kajetan Juszczak; Andrzej Wojciech Stelmach
Journal:  Cent European J Urol       Date:  2013-11-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.